Helix BioPharma Corp. (TSX: HBP, OTC: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company, announced the voting results from its Annual General and Special Meeting held on January 30, 2026. With 81.03% of outstanding shares represented, shareholders voted overwhelmingly in favor of all items of business, including the re-election of four director nominees and a resolution to amend the company's articles to effect a share consolidation of up to five pre-consolidation shares for one post-consolidation share.
The four director nominees—Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube—were each re-elected with 99.99% of votes cast in favor. The appointment of Clearhouse LLP as auditor for the ensuing year was also approved with 99.99% support. The consolidation resolution, which authorizes the board to determine the final ratio at its sole discretion, passed with 99.99% approval.
The strong shareholder endorsement underscores confidence in Helix's strategic direction, particularly its lead candidate Tumour Defence Breaker™ L-DOS47, an antibody-enzyme conjugate (AEC) targeting CEACAM6-expressing solid tumors. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC), and the company is developing novel bi-specific ADCs in discovery. Helix's pipeline aims to address hard-to-treat cancers by modulating the tumor microenvironment to enhance anti-cancer immunity.
The consolidation move is a common strategy for clinical-stage biotech firms to maintain listing requirements and attract institutional investors. Helix's stock trades on multiple exchanges, and the consolidation could improve its share price and marketability. The company's focus on CEACAM6, a prevalent tumor antigen, positions it in a competitive space where precision oncology is increasingly valued.
Helix's CEO, Thomas Mehrling, emphasized the importance of shareholder support as the company advances its clinical programs. Detailed voting results will be filed on SEDAR+ at www.sedarplus.com. For more information about Helix and its pipeline, visit https://www.helixbiopharma.com.
Forward-looking statements in the release highlight risks including financing needs, clinical trial timelines, and regulatory approvals. These factors, detailed in the company's filings on SEDAR+, could cause actual results to differ materially. Shareholders and investors are advised to review these risks as Helix progresses toward its goal of making hard-to-treat cancers vincible.
